These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 3072274)

  • 1. The pathochemical perspectives of Parkinson's disease. An attempt at a neurochemical definition.
    Hornykiewicz O
    Funct Neurol; 1988; 3(4):379-91. PubMed ID: 3072274
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopaminergic innervation of the human striatum in Parkinson's disease.
    Papapetropoulos S; Basel M; Mash DC
    Mov Disord; 2007 Jan; 22(2):286-8. PubMed ID: 17083095
    [No Abstract]   [Full Text] [Related]  

  • 3. [Striatal dopamine availability in Parkinson's disease--with reference to the wearing-off phenomenon].
    Indo T
    Rinsho Shinkeigaku; 1984 Oct; 24(10):1008-16. PubMed ID: 6518691
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.
    Elsworth JD; Roth RH
    Exp Neurol; 1997 Mar; 144(1):4-9. PubMed ID: 9126143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.
    Marek K; Jennings D; Seibyl J
    Ann Neurol; 2003; 53 Suppl 3():S160-6; discussion S166-9. PubMed ID: 12666107
    [No Abstract]   [Full Text] [Related]  

  • 6. Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum.
    Fuxe K; Strömberg I; Popoli P; Rimondini-Giorgini R; Torvinen M; Ogren SO; Franco R; Agnati LF; Ferré S
    Adv Neurol; 2001; 86():345-53. PubMed ID: 11553995
    [No Abstract]   [Full Text] [Related]  

  • 7. "Ottorino Rossi" Award 2000. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology.
    Greenamyre JT
    Funct Neurol; 2000; 15(2):67-80. PubMed ID: 10916718
    [No Abstract]   [Full Text] [Related]  

  • 8. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease.
    Lang AE; Obeso JA
    Ann Neurol; 2004 Jun; 55(6):761-5. PubMed ID: 15174009
    [No Abstract]   [Full Text] [Related]  

  • 9. Parkinson's disease and RLS: the dopaminergic bridge.
    Rye DB
    Sleep Med; 2004 May; 5(3):317-28. PubMed ID: 15165542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.
    Di Rocco A; Werner P
    Ann Neurol; 2000 Jan; 47(1):136-7. PubMed ID: 10632116
    [No Abstract]   [Full Text] [Related]  

  • 11. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O
    Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
    [No Abstract]   [Full Text] [Related]  

  • 12. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of dopamine and Zn2+ on the induction of PC12 cell death and dopamine depletion in the striatum: possible implication in the pathogenesis of Parkinson's disease.
    Lo HS; Chiang HC; Lin AM; Chiang HY; Chu YC; Kao LS
    Neurobiol Dis; 2004 Oct; 17(1):54-61. PubMed ID: 15350965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopaminergic innervation of the human striatum in Parkinson's disease.
    Porritt M; Stanic D; Finkelstein D; Batchelor P; Lockhart S; Hughes A; Kalnins R; Howells D
    Mov Disord; 2005 Jul; 20(7):810-8. PubMed ID: 15726582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The changes of striatal dopamine levels in the brain in rat models for Parkinson's disease after gene therapy].
    Tong H; Zhang J; Xu Q
    Zhonghua Yi Xue Za Zhi; 1996 Jul; 76(7):490-2. PubMed ID: 9275495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 20. Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats.
    Ueda H; Sato K; Okumura F; Inoue A; Nakata Y; Ozaki N; Yue JL; Misu Y
    Biomed Pharmacother; 1995; 49(4):169-77. PubMed ID: 7669936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.